Glaukos

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology.

CEO

Thomas William Burns

CEOThomas William Burns

Employees

907

Employees907

Headquarters

Aliso Viejo, California

HeadquartersAliso Viejo, California

Founded

1998

Founded1998

Employees

907

Employees907

GKOS Key Statistics

Market cap

5.35B

Market cap5.35B

Price-Earnings ratio

-36.97

Price-Earnings ratio-36.97

Dividend yield

—

Dividend yield—

Average volume

492.19K

Average volume492.19K

High today

$107.25

High today$107.25

Low today

$101.57

Low today$101.57

Open price

$105.73

Open price$105.73

Volume

507.24K

Volume507.24K

52 Week high

$108.22

52 Week high$108.22

52 Week low

$49.19

52 Week low$49.19

GKOS News

Benzinga 2d

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst

Loading... Loading... Thursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the consens...

Yahoo Finance 3d

Glaukos Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Glaukos (GKOS) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.59 per shar...

TipRanks 3d

Glaukos First-Quarter 2024 Financial Performance Overview - TipRanks.com - TipRanks

Glaukos (GKOS) has shared an update. Glaukos Corporation has released its first-quarter financial summary for 2024, offering investors a glimpse into the compa...

Analyst ratings

67%

of 15 ratings

Buy

66.7%

Hold

33.3%

Sell

More GKOS News

TipRanks 3d

Glaukos reports Q1 EPS (70c), consensus (57c)

Reports Q1 revenue $85.6M, consensus $79.6M. “Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burn...

Yahoo Finance 3d

Glaukos Announces First Quarter 2024 Financial Results - Yahoo Finance

ALISO VIEJO, Calif., May 01, 2024--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on nov...